GLPwatch
Zepbound for Cardiovascular risk reduction
tirzepatide · Investigational / off-label
Last updated 2026-05-28 15:46 UTCZepbound (tirzepatide) is not FDA-approved for cardiovascular risk reduction, and any use for this purpose is off-label or investigational. Research includes studies on its effects on cardiovascular risk biomarkers, blood pressure, and major adverse cardiovascular events, but these findings are not conclusive for approval.
AI summary of the sources below.
| Drug | Zepbound (tirzepatide) |
|---|---|
| Condition | Cardiovascular risk reduction |
| Approval status | Investigational / off-label |
| Research papers | 50 |
Zepbound is not FDA-approved for cardiovascular risk reduction; the research below reflects investigational or off-label study only.
Research on tirzepatide for cardiovascular risk reduction (50)
- Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial.
- Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis.
- Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: SURPASS-CVOT design and baseline characteristics.
- The dual glucose-dependent insulinotropic peptide and glucagon-like peptide-1 receptor agonist, tirzepatide, improves lipoprotein biomarkers associated with insulin resistance and cardiovascular risk in patients with type 2 diabetes.
- The dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist tirzepatide improves cardiovascular risk biomarkers in patients with type 2 diabetes: A post hoc analysis.
- The dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide: a novel cardiometabolic therapeutic prospect.
- Tirzepatide reduces the predicted risk of atherosclerotic cardiovascular disease and improves cardiometabolic risk factors in adults with obesity or overweight: SURMOUNT-1 post hoc analysis.
- Tirzepatide attenuates lipopolysaccharide-induced left ventricular remodeling and dysfunction by inhibiting the TLR4/NF-kB/NLRP3 pathway.
- Tirzepatide Reduces 24-Hour Ambulatory Blood Pressure in Adults With Body Mass Index ≥27 kg/m<sup>2</sup>: SURMOUNT-1 Ambulatory Blood Pressure Monitoring Substudy.
- Next Generation Antiobesity Medications: Setmelanotide, Semaglutide, Tirzepatide and Bimagrumab: What do They Mean for Clinical Practice?
- Risk of major adverse cardiovascular events and stroke associated with treatment with GLP-1 or the dual GIP/GLP-1 receptor agonist tirzepatide for type 2 diabetes: A systematic review and meta-analysis.
- Lifetime Health Effects and Cost-Effectiveness of Tirzepatide and Semaglutide in US Adults.
- Systolic blood pressure reduction with tirzepatide in patients with type 2 diabetes: insights from SURPASS clinical program.
- Predictors of ≥15% Weight Reduction and Associated Changes in Cardiometabolic Risk Factors With Tirzepatide in Adults With Type 2 Diabetes in SURPASS 1-4.
- Effect of tirzepatide on blood pressure and lipids: A meta-analysis of randomized controlled trials.
- Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes.
- Evidence that tirzepatide protects against diabetes-related cardiac damages.
- Bridging the gap between GLP1-receptor agonists and cardiovascular outcomes: evidence for the role of tirzepatide.
- Beyond glycemia: Comparing tirzepatide to GLP-1 analogues.
- Tirzepatide and major adverse limb events: Insights from a multicenter real-world analysis in PAD and diabetes patients.
- Risk of major adverse cardiovascular events and all-cause mortality under treatment with GLP-1 RAs or the dual GIP/GLP-1 receptor agonist tirzepatide in overweight or obese adults without diabetes: a systematic review and meta-analysis.
- Updated Meta-Analysis Assessing the Cardiovascular Efficacy of Tirzepatide.
- Tirzepatide: A novel cardiovascular protective agent in type 2 diabetes mellitus and obesity.
- The Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide Attenuates Colon Cancer Development by Regulating Glucose Metabolism.
- Tirzepatide Immunogenicity on Pharmacokinetics, Efficacy, and Safety: Analysis of Data From Phase 3 Studies.